Inhibiting the androgen receptor (AR) pathway triggers compensatory upregulation of the PI3K-AKT survival pathway in prostate cancer cells, regardless of PTEN status. Under normal conditions, AR suppresses AKT. When AR pathway inhibitors block this restraint, combined with PTEN loss removing the brakes on PIP3, AKT signaling is heavily amplified, driving unchecked tumor growth and circumventing hormone therapy.
In the CAPITELO-281 trial, one-third of prostate cancer patients with PTEN deficiency demonstrated radiographic or clinical progression without meeting standard PSA progression criteria. Dr. Neeraj Agarwal stresses that clinicians should not rely on PSA monitoring alone in this cohort. Instead, oncologists must convince reluctant patients to undergo routine CT, bone, or PSMA PET scans to avoid catastrophic consequences like paraplegia from unmonitored spinal cord compression.
High-risk features in localized prostate cancer—such as lymph node positivity or T3 disease—strongly correlate with PTEN deficiency. Dr. Neeraj Agarwal preemptively orders PTEN testing at the locally advanced stage and secures insurance approval while tissue is readily available. If patients eventually develop metastatic disease, clinicians avoid losing crucial four-to-six-week turnaround windows waiting on biopsies and approvals before initiating targeted therapy like capivasertib.
Despite clinicians frequently administering docetaxel triplets to high-risk metastatic hormone-sensitive prostate cancer patients, no prospective trial supports docetaxel specifically in PTEN-deficient disease or proves chemotherapy triplets outperform ADT plus ARPI. Dr. Neeraj Agarwal emphasizes that capivasertib paired with abiraterone is backed by Level 1 prospective evidence from the CAPITELO-281 trial. Clinicians should follow evidence-based targeted regimens rather than unvalidated chemotherapy in this molecular subset.
Unlike clinical trials with rigid protocols, real-world oncology allows clinicians to begin targeted therapies like capivasertib at full doses and proactively monitor patients over the first two to three months. This window allows physicians to detect early adverse reactions and dose-reduce prior to grade 3 or 4 toxicities emerging. Starting at lower doses risks depriving patients of therapeutic efficacy, whereas dose reductions after starting full dose do not compromise survival outcomes.
Prostate cancer patients harboring PTEN loss often experience immediate pain reduction within one to two months of starting ADT plus ARPI doublet therapy. However, Dr. Neeraj Agarwal cautions that this symptom relief can be misleading: tumors with targetable alterations like PTEN deficiency or HRR mutations progress significantly faster. Oncologists must counsel patients not to forgo adding third-agent targeted therapy simply because their symptoms improved rapidly.
Oligometastatic prostate cancer accompanied by PTEN loss behaves aggressively and rapidly converts into polymetastatic disease or castration resistance. Dr. Neeraj Agarwal warns against being misled by low volume into using metastasis-directed radiation. Radiation trials lack large phase 3 confirmation and perform poorly in tumor suppressor gene mutations. Oncologists should proceed straight to aggressive systemic targeted therapy rather than wasting time arranging oligometastatic radiation.